Answer:
Based on the information provided in the press release titled “Anaptys Announces Second Quarter 2025 Financial Results and Provides Business Update” (published August 6 2025 via GlobeNewswire), there is no mention of any changes to the company’s FY 2025 or FY 2026 guidance.
Why this conclusion is reasonable:
| What the release covers | What is not in the release |
|---|---|
| • Q2 2025 financial results (revenue, expenses, cash, etc.) • Business update (program progress, milestones, etc.) |
• Any statement that the FY 2025 or FY 2026 guidance was revised up or down • New guidance figures or ranges for FY 2025 or FY 2026 • A note that guidance remains unchanged (the press release would typically state this explicitly) |
| • The press‑release header and the summary you provided do not contain a “guidance” section. | • Any direct language such as “we raise our FY 2025 guidance to $X‑$Y” or “we are lowering FY 2026 guidance due to …”. |
What this means for you:
- If you need the most up‑to‑date guidance (whether it has changed or stayed the same), you’ll need to review the full press release or the company’s investor‑relations website for the full Q2 2025 earnings release. Companies typically include a “Guidance” section if any adjustments are being made; its absence in the summary suggests no change was announced.
- If the company had actually changed its guidance, that change would normally be highlighted in the “Business Update” or a dedicated “Guidance” subsection, which would have been reflected in the summary. Since it isn’t, we can conclude that the press release did not announce any guidance changes for FY 2025 or FY 2026.
Bottom line: The press release you shared does not indicate any revision—upward, downward, or otherwise—to AnaptysBio’s FY 2025 or FY 2026 guidance. If you need definitive confirmation, you should consult the complete earnings release or contact AnaptysBio’s investor‑relations team.
Other Questions About This News
Does the company plan to issue additional equity or debt following the capital raise mentioned?
Were there any notable regulatory filings (e.g., IND, NDA, or FDA meetings) mentioned for upcoming quarters?
Which clinical programs advanced to next‑phase trials and what are their expected timelines?
What is the updated cash runway and burn rate after the reported results?
How did AnaptysBio's Q2 2025 revenue and net loss compare to analyst expectations?
Did the company announce any new partnerships, licensing deals, or collaborations in the update?
Are there any upcoming catalysts (e.g., data readouts, conference presentations) that could move the share price?
How does the updated net cash position affect the potential for future M&A activity?
How does the current R&D expense level compare to peers in the immunology biotech space?
What are the risks highlighted in the management discussion that could affect future performance?
What impact might the Q2 results have on the stock's short‑term technical momentum?